Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $731,020 | 62 | 93.3% |
| Consulting Fee | $35,055 | 5 | 4.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,265 | 2 | 1.3% |
| Food and Beverage | $3,578 | 99 | 0.5% |
| Travel and Lodging | $3,175 | 12 | 0.4% |
| Education | $20.33 | 3 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $296,553 | 8 | $0 (2020) |
| Teva Pharmaceuticals USA, Inc. | $206,935 | 15 | $0 (2020) |
| 3M Company | $154,690 | 2 | $0 (2018) |
| Glenmark Pharmaceuticals Inc. | $66,400 | 6 | $0 (2017) |
| West-Ward Pharmaceuticals | $31,883 | 2 | $0 (2018) |
| Mylan Specialty L.P. | $13,256 | 19 | $0 (2020) |
| OptiNose US, Inc. | $2,727 | 10 | $0 (2019) |
| Chiesi USA, Inc. | $2,435 | 3 | $0 (2022) |
| Cipla USA Inc. | $2,210 | 17 | $0 (2019) |
| GlaxoSmithKline, LLC. | $1,871 | 31 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $200.90 | 7 | Regeneron Healthcare Solutions, Inc. ($103.23) |
| 2023 | $239.19 | 11 | AstraZeneca Pharmaceuticals LP ($67.39) |
| 2022 | $2,576 | 11 | Chiesi USA, Inc. ($2,435) |
| 2021 | $479.34 | 11 | AstraZeneca Pharmaceuticals LP ($341.27) |
| 2020 | $69,147 | 22 | Hikma Pharmaceuticals USA ($31,255) |
| 2019 | $393,005 | 55 | Hikma Pharmaceuticals USA ($265,298) |
| 2018 | $91,496 | 37 | 3M Company ($55,248) |
| 2017 | $225,969 | 29 | 3M Company ($99,442) |
All Payment Transactions
183 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: RESPIRATORY | ||||||
| 10/08/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.25 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/24/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: Respiratory | ||||||
| 05/07/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $33.42 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/27/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.56 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/15/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $30.74 | General |
| Category: RESPIRATORY | ||||||
| 02/13/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $27.44 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 11/14/2023 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $27.88 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 11/09/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $29.64 | General |
| Category: RESPIRATORY | ||||||
| 10/31/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $21.48 | General |
| 10/24/2023 | PFIZER INC. | EUCRISA (Drug), CIBINQO | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: DERMATOLOGY | ||||||
| 10/18/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: Respiratory | ||||||
| 09/20/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/05/2023 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $27.94 | General |
| Category: DERMATOLOGY | ||||||
| 07/28/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: Respiratory | ||||||
| 06/07/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: Respiratory | ||||||
| 05/18/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/19/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Respiratory | ||||||
| 10/27/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: RESPIRATORY | ||||||
| 10/27/2022 | Novartis Pharmaceuticals Corporation | XOLAIR (Biological) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: RESPIRATORY | ||||||
| 10/03/2022 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: Respiratory | ||||||
| 08/06/2022 | Chiesi USA, Inc. | — | — | Cash or cash equivalent | $401.00 | Research |
| Study: CLI-05993AB8-02 | ||||||
| 08/06/2022 | Chiesi USA, Inc. | — | — | Cash or cash equivalent | $266.48 | Research |
| Study: CLI-05993AB8-02 | ||||||
| 08/06/2022 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: Respiratory | ||||||
| 08/04/2022 | Chiesi USA, Inc. | — | — | Cash or cash equivalent | $1,767.68 | Research |
| Study: CLI-05993AB8-02 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study | Hikma Pharmaceuticals USA | $265,298 | 6 |
| CSP-07-000034 | 3M Company | $154,690 | 2 |
| A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $148,137 | 12 |
| GSP 301-303 | Glenmark Pharmaceuticals Inc. | $66,400 | 6 |
| ACT-2015-075-OAA | Teva Pharmaceuticals USA, Inc. | $58,783 | 2 |
| Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study | West-Ward Pharmaceuticals | $31,883 | 2 |
| CLI-05993AB8-02 | Chiesi USA, Inc. | $2,435 | 3 |
| U-FS-MU-AS3120 | Cipla USA Inc. | $2,210 | 17 |
| Ph2b moderate to severe high reversibility asthma | Amgen Inc. | $162.63 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 557 | 15,657 | $1.6M | $398,489 |
| 2022 | 16 | 681 | 17,145 | $1.2M | $363,448 |
| 2021 | 16 | 1,045 | 11,007 | $248,516 | $142,388 |
| 2020 | 17 | 743 | 9,454 | $199,662 | $109,621 |
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 15 | 10,110 | $1.3M | $306,126 | 23.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 136 | 400 | $70,000 | $27,857 | 39.8% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 37 | 1,553 | $65,226 | $20,465 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 90 | 140 | $28,000 | $13,351 | 47.7% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 77 | 235 | $23,970 | $7,268 | 30.3% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 78 | 730 | $25,550 | $6,357 | 24.9% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 24 | 1,735 | $26,025 | $6,176 | 23.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 34 | 34 | $11,050 | $4,451 | 40.3% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 20 | 456 | $10,944 | $3,332 | 30.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 25 | 237 | $33,945 | $2,879 | 8.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 21 | 27 | $495.00 | $226.80 | 45.8% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 12 | 8,085 | $977,402 | $240,861 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 180 | 589 | $64,480 | $41,739 | 64.7% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 53 | 3,935 | $57,140 | $35,111 | 61.4% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 34 | 2,377 | $18,071 | $8,644 | 47.8% |
| 94375 | Test to measure rate of airflow | Office | 2022 | 82 | 271 | $15,266 | $8,604 | 56.4% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 63 | 820 | $20,598 | $7,575 | 36.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 48 | 62 | $8,620 | $5,870 | 68.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 34 | 34 | $7,600 | $4,190 | 55.1% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2022 | 23 | 476 | $4,284 | $3,398 | 79.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 22 | 184 | $27,305 | $2,352 | 8.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 30 | 30 | $2,250 | $2,056 | 91.4% |
| 95115 | Professional service for single injection of allergen | Office | 2022 | 17 | 182 | $3,735 | $1,423 | 38.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 30 | 30 | $900.00 | $882.00 | 98.0% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 11 | 18 | $978.00 | $435.58 | 44.5% |
About Dr. Warren Pleskow, MD
Dr. Warren Pleskow, MD is a Internal Medicine healthcare provider based in Encinitas, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942313036.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Warren Pleskow, MD has received a total of $783,113 in payments from pharmaceutical and medical device companies, with $200.90 received in 2024. These payments were reported across 183 transactions from 24 companies. The most common payment nature is "" ($731,020).
As a Medicare-enrolled provider, Pleskow has provided services to 3,026 Medicare beneficiaries, totaling 53,263 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Allergy & Immunology
- Location Encinitas, CA
- Active Since 08/16/2006
- Last Updated 09/11/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1942313036
Products in Payments
- Fluticasone Salmeterol (Drug) $297,181
- Fluticasone Propionate and Salmeterol (Biological) $117,537
- Budesonide/Formoterol fumarate dihydrate (Drug) $58,783
- FLUTICASONE PROPIONATE AND SALMETEROL (Drug) $33,465
- Fluticasone Propionate and Salmeterol (Drug) $30,600
- Yupelri (Drug) $13,256
- Xhance (Drug) $2,727
- DUPIXENT (Biological) $466.03
- NUCALA (Biological) $389.06
- FASENRA (Biological) $338.20
- FASENRA (Drug) $226.89
- Haegarda (Biological) $205.13
- XOLAIR (Biological) $162.75
- EUCRISA (Drug) $140.79
- DUPIXENT DUPILUMAB INJECTION (Biological) $125.10
- CUVITRU (Biological) $124.71
- TRELEGY ELLIPTA (Drug) $123.92
- Prolastin-C (Biological) $121.08
- XOLAIR (Drug) $55.32
- SYMBICORT (Drug) $40.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Encinitas
Alberto Bessudo, M.d, M.D
Internal Medicine — Payments: $98,717
Dr. Amanda Lloyd, M.d, M.D
Internal Medicine — Payments: $89,204
Vikram Garg, Md, MD
Internal Medicine — Payments: $65,593
Dr. Natalie Maclean, Md, Msc, Frcpc, MD, MSC, FRCPC
Internal Medicine — Payments: $22,124
Dr. Robert Stephenson, M.d, M.D
Internal Medicine — Payments: $11,171
Janki Patel, M.d, M.D
Internal Medicine — Payments: $6,528